Evidence map›Paper›PMID 25418579›Full record

ArticleLaboratory investigation; a journal of technical methods and pathology2015

Generation of a murine hepatic angiosarcoma cell line and reproducible mouse tumor model.

Sonja Rothweiler, Michael T Dill, Luigi Terracciano, Zuzanna Makowska, Luca Quagliata, Ruslan Hlushchuk, Valentin Djonov, Markus H Heim, David Semela

Abstract read
PubMed Publisher
In one paragraph

Article in Laboratory investigation; a journal of technical methods and pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Biomolecules · 2022
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sonja RothweilerDepartment of Biomedicine, University Basel, Basel, Switzerland.
Michael T DillDepartment of Biomedicine, University Basel, Basel, Switzerland.
Luigi TerraccianoInstitute of Pathology, University Hospital Basel, Basel, Switzerland.
Zuzanna MakowskaDepartment of Biomedicine, University Basel, Basel, Switzerland.
Luca QuagliataInstitute of Pathology, University Hospital Basel, Basel, Switzerland.
Ruslan HlushchukInstitute of Anatomy, University of Bern, Bern, Switzerland.
Valentin DjonovInstitute of Anatomy, University of Bern, Bern, Switzerland.
Markus H Heim1] Department of Biomedicine, University Basel, Basel, Switzerland [2] Division of Gastroenterology and Hepatology, University Hospital Basel, Basel, Switzerland.ORCID 0000000275234894
David Semela1] Department of Biomedicine, University Basel, Basel, Switzerland [2] Division of Gastroenterology and Hepatology, Kantonsspital St. Gallen, St. Gallen, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatic angiosarcoma (AS) is a rare and highly aggressive tumor of endothelial origin with dismal prognosis. Studies of the molecular biology of AS and treatment options are limited as animal models are rare. We have previously shown that inducible knockout of Notch1 in mice leads to spontaneous formation of hepatic AS. The aims of this study were to: (1) establish and characterize a cell line derived from this murine AS, (2) identify molecular pathways involved in the pathogenesis and potential therapeutic targets, and (3) generate a tumor transplantation model. AS cells retained specific endothelial properties such as tube formation activity, as well as expression of CD31 and Von Willebrand factor. However, electron microscopy analysis revealed signs of dedifferentiation with loss of fenestrae and loss of contact inhibition. Microarray and pathway analysis showed substantial changes in gene expression and revealed activation of the Myc pathway. Exposing the AS cells to sorafenib reduced migration, filopodia dynamics, and cell proliferation but did not induce apoptosis. In addition, sorafenib suppressed ERK phosphorylation and expression of cyclin D2. Injection of AS cells into NOD/SCID mice resulted in formation of undifferentiated tumors, confirming the tumorigenic potential of these cells. In summary, we established and characterized a murine model of spontaneous AS formation and hepatic AS cell lines as a useful in vitro tool. Our data demonstrate antitumor activity of sorafenib in AS cells with potent inhibition of migration, filopodia formation, and cell proliferation, supporting further evaluation of sorafenib as a novel treatment strategy. In addition, AS cell transplantation provides a subcutaneous tumor model useful for in vivo preclinical drug testing.

Indexed as

Disease Models, AnimalAnimalsAntineoplastic AgentsApoptosisCell Line, TumorCell ProliferationCells, CulturedGene Expression Regulation, NeoplasticHemangiosarcomaImmunohistochemistryLiverLiver NeoplasmsMice, Inbred C57BLMice, Inbred NODMice, KnockoutMice, SCIDAntineoplastic AgentsNiacinamideNotch1 protein, mousePhenylurea CompoundsReceptor, Notch1Sorafenib

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.